Literature DB >> 25121004

Garenoxacin in Skin and Skin Structure Infections Sustained due to Road Traffic Accident.

Mahesh Mohanlal Pukar1, Anoop Laxminarayan Hajare2, K Krishnaprasad3, Amit Indra Bhargava4.   

Abstract

Skin and soft tissue infections represent a continuum of symptoms that range from uncomplicated cellulitis to the potentially lethal entity necrotizing fasciitis that is often considered to be microbial invasions of the epidermis, dermis and subcutaneous tissues. Garenoxacin, a newer oral des-fluoroquinolone having potent antimicrobial activity against wide variety of common pathogens involved in skin and skin structure infections (SSTIs), including the resistant strains offer the advantage of broad spectrum of coverage including gram positive, gram negative and anaerobic organisms. This case study indicates the utility of garenoxacin in treating skin and soft tissue infections caused by road traffic accidents.

Entities:  

Keywords:  Broad-spectrum antibiotic; Newer fluoroquinolone; Resistance; SSTI; Wounds

Year:  2014        PMID: 25121004      PMCID: PMC4129297          DOI: 10.7860/JCDR/2014/9066.4458

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  10 in total

1.  Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.

Authors:  J C Fung-Tomc; B Minassian; B Kolek; E Huczko; L Aleksunes; T Stickle; T Washo; E Gradelski; L Valera; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

2.  Managing skin and soft tissue infections: expert panel recommendations on key decision points.

Authors:  Lawrence J Eron; Benjamin A Lipsky; Donald E Low; Dilip Nathwani; Alan D Tice; Gregory A Volturo
Journal:  J Antimicrob Chemother       Date:  2003-11       Impact factor: 5.790

Review 3.  Complicated skin and soft tissue infection.

Authors:  Matthew S Dryden
Journal:  J Antimicrob Chemother       Date:  2010-11       Impact factor: 5.790

Review 4.  Skin and soft tissue infections.

Authors:  Robert L Rogers; Jack Perkins
Journal:  Prim Care       Date:  2006-09       Impact factor: 2.907

5.  Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000).

Authors:  Robert P Rennie; Ronald N Jones; Alan H Mutnick
Journal:  Diagn Microbiol Infect Dis       Date:  2003-04       Impact factor: 2.803

Review 6.  Skin and soft tissue infections.

Authors:  Addison K May
Journal:  Surg Clin North Am       Date:  2009-04       Impact factor: 2.741

Review 7.  Clinical studies of garenoxacin.

Authors:  Hiroyasu Takagi; Kiyoshi Tanaka; Hisatsugu Tsuda; Hiroyuki Kobayashi
Journal:  Int J Antimicrob Agents       Date:  2008-09-13       Impact factor: 5.283

8.  Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects.

Authors:  D A Gajjar; A Bello; Z Ge; L Christopher; D M Grasela
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

9.  Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000).

Authors:  Jeffrey T Kirby; Alan H Mutnick; Ronald N Jones; Douglas J Biedenbach; Michael A Pfaller
Journal:  Diagn Microbiol Infect Dis       Date:  2002-08       Impact factor: 2.803

Review 10.  Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials.

Authors:  Brad Spellberg; George H Talbot; Helen W Boucher; John S Bradley; David Gilbert; W Michael Scheld; John Edwards; John G Bartlett
Journal:  Clin Infect Dis       Date:  2009-08-01       Impact factor: 9.079

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.